Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 2/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.44 |
| ▸ | EGLN2 | Q96KS0 | 2/20 | 0.40 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.32 |
| ▸ | JAK2 | O60674 | 2/20 | 0.32 |
| ▸ | AURKA | O14965 | 1/20 | 0.32 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.32 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.32 |
| ▸ | PAK4 | O96013 | 1/20 | 0.32 |
| ▸ | ABL1 | P00519 | 1/20 | 0.32 |
| ▸ | CSF1R | P07333 | 1/20 | 0.32 |
| ▸ | RET | P07949 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24300299 | 0.79 | HTT (0.34) | CYP11B1CYP11B2CHEK1HTTKMT2A | |
| SCHEMBL29929823 | 0.78 | EGLN2 (0.42) | CYP11B1CYP11B2EGLN2KMT2APIK3CD | |
| SCHEMBL186339 | 0.78 | EGLN2 (0.42) | CYP11B1CYP11B2EGLN2KMT2APIK3CD | |
| SCHEMBL4719121 | 0.78 | KMT2A (0.46) | CYP11B1CYP11B2CHEK1HTTKMT2A | |
| SCHEMBL1630093 | 0.75 | ALDH1A1 (0.44) | CYP11B1CYP11B2CHEK1HTTKMT2A | |
| SCHEMBL17696193 | 0.75 | CHEK1 (0.37) | CYP11B1CYP11B2CHEK1HTTKMT2A | |
| SCHEMBL16429389 | 0.75 | CHEK1 (0.37) | CYP11B1CYP11B2CHEK1HTTKMT2A | |
| SCHEMBL855910 | 0.75 | PIK3CD (0.51) | CYP11B1CYP11B2CHEK1HTTKMT2A | |
| SCHEMBL2076123 | 0.75 | CHEK1 (0.37) | CYP11B1CYP11B2CHEK1HTTKMT2A | |
| SCHEMBL3189266 | 0.75 | EGLN2 (0.40) | CYP11B1CYP11B2EGLN2HTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 528 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117865953-A | Preparation method of 7H-indole [2,3-c ] quinoline derivatives based on phosphorescent moieties and having photoresponse | 北京化工大学 | 2024-04-12 | — | — | CN | claimed |
| WO-2026090589-A1 | HETEROCYCLIC HBS1L DEGRADERS | TANGO THERAPEUTICS, INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| US-12583839-B2 | PD-L1 antagonist compound | ADLAI NORTYE BIOPHARMA CO., LTD. (CN) | 2026-03-24 | — | — | US | disclosed |
| US-12577226-B2 | Compounds for treating Huntington's disease | PTC THERAPEUTICS, INC. (US) | 2026-03-17 | — | — | US | disclosed |
| US-20260070932-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON INC (US) | 2026-03-12 | — | — | US | disclosed |
| US-12528822-B2 | Cycloalkane-1,3-diamine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2026-01-20 | — | — | US | disclosed |
| US-12514251-B2 | Fused heterocyclic compounds and their use as pest control agents | PI INDUSTRIES LTD. (IN) | 2026-01-06 | — | — | US | disclosed |
| US-20260001870-A1 | INHIBITOR COMPOUNDS | Cincera Therapeutics Pty Ltd (AU) | 2026-01-01 | — | — | US | disclosed |
| US-12509431-B2 | 1,4-dihydroquinazolinone compounds and uses thereof | EDGEWISE THERAPEUTICS, INC. (US) | 2025-12-30 | — | — | US | disclosed |
| US-12509474-B2 | Inhibitors of complement factors and uses thereof | ANNEXON, INC. (US) | 2025-12-30 | — | — | US | disclosed |
| US-20090062349-A1 | 1-Hydroxycycloalkanecarboxamide derivatives | MERCK SHARP & DOHME LLC | 2009-03-05 | — | — | US | disclosed |
| US-20080318976-A1 | Alpha-Hydroxy Amides as Bradykinin Antagonists or Inverse Agonists | MERCK SHARP & DOHME CORP. | 2008-12-25 | — | — | US | disclosed |
| EP-1979314-A2 | INDOLE SULFONAMIDE MODULATORS OF PROGESTERONE RECEPTORS | Eli Lilly & Company (US) | 2008-10-15 | — | — | EP | disclosed |
| WO-2007087488-A9 | INDOLE SULFONAMIDE MODULATORS OF PROGESTERONE RECEPTORS | LILLY CO ELI (US) | 2008-08-28 | — | — | WO | disclosed |
| EP-1893579-A1 | 1-HYDROXYCYCLOALKANECARBOXAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | Merck & Co., Inc. (US) | 2008-03-05 | — | — | EP | disclosed |
| WO-2007118572-A1 | LIQUID-CRYSTALLINE MIXTURES AND LIQUID-CRYSTAL DISPLAYS | MERCK PATENT GMBH (DE) | 2007-10-25 | — | — | WO | disclosed |
| WO-2007087488-A2 | INDOLE SULFONAMIDE MODULATORS OF PROGESTERONE RECEPTORS | ELI LILLY AND COMPANY (US) | 2007-08-02 | — | — | WO | disclosed |
| WO-2006132837-A1 | l-HYDROXYCYCLOALKANECARBOXAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | MERCK & CO., INC. (US) | 2006-12-14 | — | — | WO | disclosed |
| EP-1706372-A1 | ALPHA-HYDROXY AMIDES AS BRADYKININ ANTAGONISTS OR INVERSE AGONISTS | Merck & Co., Inc. (US) | 2006-10-04 | — | — | EP | disclosed |
| WO-2005063690-A1 | ALPHA-HYDROXY AMIDES AS BRADYKININ ANTAGONISTS OR INVERSE AGONISTS | MERCK & CO., INC. (US) | 2005-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318976-A1 | Alpha-Hydroxy Amides as Bradykinin Antagonists or Inverse Agonists | BDKRB1, BDKRB2, HCAR2 | CYP11B1 1094/4885CYP11B2 1232/4885EGLN2 930/4885 |
| US-12509431-B2 | 1,4-dihydroquinazolinone compounds and uses thereof | TNNT2, TNNI3, TNNC1 | CYP11B1 23/4885CYP11B2 39/4885EGLN2 1904/4885 |
| US-12509474-B2 | Inhibitors of complement factors and uses thereof | SSB, UACA, CFH | CYP11B1 2889/4885CYP11B2 2741/4885EGLN2 740/4885 |
| US-12577226-B2 | Compounds for treating Huntington's disease | HTT, HYPK, GRIN2C | CYP11B1 400/4885CYP11B2 612/4885EGLN2 475/4885 |
| US-20260001870-A1 | INHIBITOR COMPOUNDS | CES1, NCEH1, NR1H2 | CYP11B1 170/4885CYP11B2 422/4885EGLN2 3320/4885 |
| US-20260070932-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | CFH, CFB, C5 | CYP11B1 1641/4885CYP11B2 1666/4885EGLN2 1917/4885 |
| US-20090062349-A1 | 1-Hydroxycycloalkanecarboxamide derivatives | BDKRB1, BDKRB2, HRH4 | CYP11B1 1402/4885CYP11B2 1614/4885EGLN2 778/4885 |
| US-12528822-B2 | Cycloalkane-1,3-diamine derivative | MLLT1, MLLT3, PRMT6 | CYP11B1 925/4885CYP11B2 1214/4885EGLN2 1204/4885 |
| US-12583839-B2 | PD-L1 antagonist compound | CD274, PDCD1LG2, PDCD1 | CYP11B1 764/4885CYP11B2 919/4885EGLN2 4426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.